Phesgo takes roughly 7 months to clear from your body after the final dose. That timeline comes from the slower-clearing of its two active components, trastuzumab, which needs about 7 months to reach near-complete washout in at least 95% of patients. The other component, pertuzumab, clears a bit faster but on a similar overall scale.
What Phesgo Contains and Why Clearance Takes Months
Phesgo is a subcutaneous injection that combines two antibody therapies, pertuzumab and trastuzumab, along with an enzyme called hyaluronidase that helps the drugs spread under the skin and absorb into your bloodstream. Because pertuzumab and trastuzumab are large antibody proteins rather than small chemical molecules, your body breaks them down slowly. Small-molecule drugs often clear in hours or days. Antibodies like these take weeks.
Each component has its own half-life, which is the time it takes for the concentration in your blood to drop by half. Pertuzumab has a half-life of about 24 days, and trastuzumab’s is about 22 days. After one half-life, half the drug remains. After two half-lives, a quarter remains. It takes many rounds of this halving before levels become negligible.
The 7-Month Washout Timeline
According to the European Medicines Agency’s analysis, trastuzumab reaches concentrations below 1 microgram per milliliter (about 97% washout) in at least 95% of patients by 7 months after the last dose. That 7-month figure is the most practical answer to “how long does it stay in your body,” because it accounts for the fact that drug levels during treatment build up over multiple cycles, meaning there’s more to clear than a single dose would suggest.
Pertuzumab clears slightly faster on a per-dose basis, with a clearance rate of 0.163 liters per day compared to trastuzumab’s 0.111 liters per day. In practice, though, both components follow a similar months-long tail. Trace amounts may technically be detectable beyond 7 months in some individuals, but by that point the levels are far below what’s considered therapeutically active.
Why This Matters for Pregnancy Planning
The 7-month washout window is especially important if you’re thinking about becoming pregnant after finishing treatment. Both pertuzumab and trastuzumab can cross the placenta and have been associated with harm to a developing fetus, including reduced amniotic fluid. The FDA labeling highlights the long half-lives of both components specifically in the context of reproductive risk. Waiting at least 7 months after your final Phesgo injection gives your body time to clear the drugs to negligible levels before conception.
Heart Monitoring After Your Last Dose
Trastuzumab-based treatments can affect heart function, specifically the heart’s pumping strength (measured as left ventricular ejection fraction). Because the drug remains active in your body for months after the last injection, heart monitoring doesn’t stop when treatment ends. Your care team will typically continue checking your heart function for a period after your final dose, reflecting the fact that the drug is still circulating and could still influence cardiac muscle during that window.
Factors That Can Shift Your Personal Timeline
The 7-month estimate applies to the broad population studied in clinical trials. Your individual clearance could be somewhat faster or slower depending on a few variables. Body weight is one factor: antibody drugs are distributed through your tissues, so body composition influences how much drug is present and how quickly it’s processed. Age, liver function, and overall health also play a role in how efficiently your body breaks down large proteins.
The number of treatment cycles you’ve completed matters too. If you received Phesgo for a full year of adjuvant therapy, your body accumulated higher steady-state levels than someone who received only a few cycles. Higher accumulated levels mean more drug to clear, though the half-life itself doesn’t change. The 7-month figure from regulatory data already accounts for patients at steady state, so it’s a reasonable benchmark for most people finishing a standard course of treatment.